Long-Term UDCA
UDCA remains the recommended first-line pharmacotherapy for PBC and is typically continued long term when tolerated.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
Size, Share & Industry Analysis, By Type (Capsules, Tablets), By Application (Primary Biliary Cholangitis, Gallstones, Cystic Fibrosis-Associated Liver Disease, Other Hepatobiliary Diseases), By End User (Hospitals, Specialty Hepatology/Gastroenterology Clinics, Primary Care & Community Practices, Homecare), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online/Mail-Order Pharmacies), By Treatment Position (First-Line Long-Term Therapy, Adjunct to Second-Line PBC Therapy, Gallstone Dissolution Therapy, Other Use), and Regional Forecast, 2026-2034
The global ursodeoxycholic acid drugs for hepatobiliary diseases market was valued at USD 1.41 billion in 2025 and is estimated at USD 1.50 billion in 2026. The market is projected to reach USD 2.40 billion by 2034, representing a 6.1% CAGR during 2026–2034.
Ursodeoxycholic acid, also known as ursodiol, is a hydrophilic bile acid used across chronic hepatobiliary disease management. The largest commercial application is primary biliary cholangitis, where AASLD identifies UDCA as the mainstay of treatment at 13–15 mg/kg/day and recommends long-term therapy in patients with abnormal liver tests.
The market also includes gallstone dissolution and selected regional hepatobiliary uses. FDA labeling for Actigall describes ursodiol capsules for dissolution of suitable gallstones and notes that therapy can require months, with recurrence reported in up to 50% of patients who achieve dissolution within five years. These characteristics create prolonged treatment duration but also limit use to carefully selected patients.
Recent PBC drug innovation is reshaping the market without removing UDCA from the treatment backbone. FDA approved IQIRVO in June 2024 and LIVDELZI in August 2024 for PBC in combination with UDCA in adults who have an inadequate response, or as monotherapy when UDCA cannot be tolerated. These approvals increase treatment layering and reinforce the importance of identifying biochemical non-response after initial UDCA therapy.
Source: AASLD treatment overview; FDA ursodiol label; FDA IQIRVO; FDA LIVDELZI.
The study defines the global ursodeoxycholic acid drugs for hepatobiliary diseases market market by the equipment, application, end-user and technology boundaries listed below. The scope is structured to keep market sizing consistent with the commercial systems and services included in the syndicated study.
| Report Attribute | Coverage |
|---|---|
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026–2034 |
| Market Measurement | Revenue, USD billion |
| By Type | Capsules; Tablets |
| By Application | Primary Biliary Cholangitis; Gallstones; Cystic Fibrosis-Associated Liver Disease; Other Hepatobiliary Diseases |
| By End User | Hospitals; Specialty Hepatology/Gastroenterology Clinics; Primary Care & Community Practices; Homecare |
| By Distribution Channel | Hospital Pharmacies; Retail Pharmacies; Online/Mail-Order Pharmacies |
| By Treatment Position | First-Line Long-Term Therapy; Adjunct to Second-Line PBC Therapy; Gallstone Dissolution Therapy; Other Use |
| By Region | North America; Europe; Asia-Pacific; Latin America; Middle East & Africa |
| Selected Countries | United States; Canada; Germany; United Kingdom; France; Italy; Japan; China; South Korea; India; Australia; Brazil; Mexico and other relevant markets |
| Key Market Players | Dr. Falk Pharma GmbH; Daewoong Pharmaceutical; Teva Pharmaceutical; Humanwell Healthcare Group; Mitsubishi Tanabe Pharma; Lannett Company; Viatris; Bruschettini S.R.L.; Impax Laboratories; Shanghai Pharmaceuticals; Grindeks; Epic Pharma; Arbor Pharmaceuticals; Galentic Pharma; Mayne Pharma |
The market includes finished ursodeoxycholic acid/ursodiol medicines used for hepatobiliary indications such as primary biliary cholangitis, gallstone dissolution and selected cholestatic or liver-disease applications. Capsules and tablets supplied through institutional and outpatient channels are included in revenue.
Second-line PBC drugs such as elafibranor and seladelpar are excluded from UDCA market revenue but are discussed because they are often used in combination with UDCA after inadequate response. Diagnostic testing, transplant services and non-UDCA bile-acid medicines are outside the core market.
AASLD identifies UDCA as the mainstay of PBC treatment at 13–15 mg/kg/day. Long-term use means diagnosed patients can remain on therapy for years, supporting recurring prescription demand even when second-line agents are added.
AASLD guidance recommends evaluating response after roughly one year of therapy. Patients with inadequate biochemical response may require additional treatment, but UDCA often remains part of the combination regimen, preserving its role in the treatment pathway.
Ursodiol is a mature molecule available from multiple manufacturers. Generic competition improves access and supports broad long-term use but shifts growth toward prescription volume and geographic expansion rather than sustained premium pricing.
Actigall labeling supports use in selected radiolucent gallstones where surgery is not appropriate or is declined. Treatment requires careful patient selection and can extend over months, creating a smaller but persistent non-PBC demand segment.
IQIRVO and LIVDELZI were approved in 2024 for adults with inadequate UDCA response or intolerance. Their arrival increases specialist attention to treatment response and creates combination use rather than immediate displacement of UDCA.
Source: AASLD; FDA ursodiol; FDA Actigall; FDA IQIRVO; FDA LIVDELZI.
The 2024 approvals of elafibranor and seladelpar formalized a treatment model in which patients with inadequate response can receive additional therapy while continuing UDCA. This shifts commercial competition from single-drug substitution toward combination treatment and response-based escalation.
Treatment decisions increasingly distinguish responders from patients with persistently elevated alkaline phosphatase or bilirubin. This creates separate commercial cohorts within the same PBC population and supports closer monitoring of therapy effectiveness.
A mature active ingredient and multiple formulation suppliers make UDCA accessible across North America, Europe and Asia. Competition therefore centers on formulation quality, supply continuity, pharmacy contracts and country-specific registration rather than patent exclusivity.
Weight-based PBC dosing creates demand for multiple strengths and convenient oral formulations. Capsule and tablet portfolios can be differentiated through pill burden, strength availability and patient adherence rather than through new molecular mechanisms.
New FDA-approved second-line therapies increase commercial attention to PBC and may encourage earlier referral, more frequent biochemical assessment and longer engagement with specialist hepatology care, indirectly supporting the underlying UDCA market.
Source: FDA IQIRVO; FDA LIVDELZI; AASLD guidance.
UDCA is a mature oral therapy whose commercial role is defined by disease indication, treatment duration and response monitoring. Innovation around the market increasingly occurs through combination therapy rather than reformulation of the bile acid itself.
UDCA remains the recommended first-line pharmacotherapy for PBC and is typically continued long term when tolerated.
Patients with inadequate biochemical response can receive newer agents such as elafibranor or seladelpar while UDCA remains part of the regimen.
Ursodiol can dissolve selected cholesterol gallstones in patients who are not candidates for or do not choose surgery, but treatment is prolonged and recurrence can occur.
UDCA is used in additional hepatobiliary conditions in some markets, although evidence and guideline support differ by indication.
Source: AASLD; FDA Actigall; FDA IQIRVO.
By type, the market is segmented into capsules and tablets. Capsules form the leading commercial segment in the syndicated scope, while tablets provide an important alternative across generic and institutional formularies.
Capsules lead the syndicated type segmentation because they are widely used for chronic UDCA therapy and support flexible dose combinations across weight-based treatment. Established brands and generics maintain broad availability.
Tablets remain an important dosage form in cost-sensitive and generic markets. Their role is supported by fixed strengths, pharmacy familiarity and suitability for long-term outpatient treatment.
Capsules are expected to remain the leading dosage form, while tablets retain a substantial role where formulary preference, strength availability and generic pricing favor solid oral alternatives.
By application, the market is segmented into primary biliary cholangitis, gallstones, cystic-fibrosis-associated liver disease and other hepatobiliary conditions. PBC is the leading application because UDCA is a guideline-supported long-term therapy.
PBC is the core commercial indication because AASLD recommends oral UDCA at 13–15 mg/kg/day in patients with abnormal liver enzymes. Long treatment duration creates recurring demand.
Ursodiol can be used for dissolution of selected gallstones when surgery is unsuitable or declined. The segment is smaller because treatment is slow, patient selection is restrictive and recurrence can occur.
UDCA is used in selected hepatobiliary manifestations associated with cystic fibrosis in some clinical settings, though practice and evidence are more variable than in PBC.
Other use includes selected cholestatic and liver-disease applications where clinicians prescribe UDCA according to local guidance, patient characteristics and regional practice.
PBC will remain the principal value and volume driver, while gallstone and other hepatobiliary applications provide smaller, regionally variable demand.
By end user, demand is distributed across hospitals, specialty hepatology and gastroenterology clinics, primary-care practices and homecare. Chronic oral therapy shifts most long-term consumption into outpatient channels after diagnosis and treatment selection.
Specialists diagnose PBC, assess biochemical response and decide when second-line therapy is needed. Their prescribing influence is high even when medicines are dispensed through retail pharmacies.
Hospitals manage newly diagnosed, advanced or complicated hepatobiliary disease and influence initiation of UDCA in patients requiring specialist evaluation.
Once diagnosis and dosing are established, stable patients can receive ongoing prescription support through community care, particularly for long-duration therapy.
Because UDCA is an oral chronic therapy, most medication administration occurs at home. Adherence, pill burden and refill continuity therefore influence real-world consumption.
Specialist clinics will remain central to treatment decisions, while the recurring revenue base is supported by long-term outpatient and home administration.
By distribution channel, the market is segmented into hospital pharmacies, retail pharmacies and online or mail-order pharmacies. Chronic oral treatment favors outpatient refill channels after specialist initiation.
Retail pharmacies handle a large share of chronic UDCA dispensing because patients require repeated oral prescriptions over long periods. Generic substitution and payer formularies strongly influence product choice.
Hospital pharmacies are important when therapy is initiated in specialist centers or when patients have advanced disease, complex comorbidities or inpatient hepatobiliary care.
Mail-order and digital pharmacy services can support refill continuity for stable chronic patients and may reduce dispensing friction in long-duration therapy.
Retail pharmacies are expected to retain the largest recurring dispensing role, while online and mail-order channels can gain share through chronic refill programs.
By treatment position, the market is segmented into first-line long-term PBC therapy, adjunct use with second-line PBC agents, gallstone dissolution therapy and other hepatobiliary use. Treatment position increasingly reflects response to initial UDCA.
UDCA remains the first-line pharmacotherapy for PBC and is generally continued when tolerated. This creates the most stable recurring demand segment in the market.
IQIRVO and LIVDELZI are approved for use with UDCA in adults who have an inadequate response. Combination use preserves UDCA volume while adding new mechanisms to the treatment pathway.
Gallstone therapy represents a secondary use where prolonged treatment and recurrence limit broad adoption but maintain a defined niche.
Other treatment positions depend on local guidance and evidence, creating heterogeneous demand that is less standardized than PBC treatment.
First-line PBC therapy will remain the market anchor, while combination use with newer second-line medicines is expected to become more important in inadequate responders.
Regional demand reflects PBC diagnosis, hepatology infrastructure, generic access and national treatment guidance. North America is the largest market, with Europe and Asia-Pacific also contributing substantial long-term therapy demand.
North America leads through established PBC diagnosis, specialty hepatology care and wide generic availability. Recent U.S. second-line approvals are increasing treatment intensity around patients who remain on UDCA.
European hepatology practice has long supported first-line UDCA in PBC, and specialist pharmaceutical companies maintain strong regional presence. Generic competition keeps pricing disciplined.
Japan, South Korea, China and India combine significant pharmaceutical manufacturing with expanding diagnosis of chronic hepatobiliary disease. Local generics broaden affordability and access.
Demand is centered in larger hepatology centers and retail generic channels, with affordability and diagnostic access shaping treatment volume.
Specialist access varies widely. Gulf markets support broader chronic liver-disease treatment, while lower-resource settings face diagnosis and medicine-access constraints.
Source: AASLD; FDA IQIRVO; FDA LIVDELZI.
UDCA is a mature therapy with an established safety and regulatory history, but its market is increasingly influenced by response-based treatment guidelines and newly approved adjunctive PBC agents.
| Framework / Event | Requirement or Development | Commercial Relevance |
|---|---|---|
| AASLD first-line recommendation | AASLD recommends oral UDCA at 13–15 mg/kg/day for PBC patients with abnormal liver tests. | Creates a durable standard-of-care foundation for long-term demand. |
| FDA PBC labeling | Ursodiol labeling includes clinical evidence in PBC patients treated at 13–15 mg/kg/day. | Supports standardized dosing and broad generic reference labeling. |
| Adjunctive second-line approvals | IQIRVO and LIVDELZI are approved with UDCA for adults who have an inadequate response. | Reinforces response monitoring and combination therapy rather than broad UDCA displacement. |
| Gallstone labeling | Actigall includes selected gallstone-dissolution use with explicit patient-selection requirements. | Limits the gallstone opportunity to clinically appropriate subgroups. |
Source: AASLD guidance; FDA ursodiol; FDA Actigall; FDA IQIRVO.
The UDCA market is a mature generic pharmaceutical category with differentiated regional brands and specialist hepatology suppliers. Competition centers on manufacturing quality, strength and dosage-form breadth, hospital and retail access, price, and the ability to maintain reliable supply for long-duration therapy.
A focused gastroenterology and hepatology portfolio supports strong specialist recognition and regional distribution.
Generic manufacturers compete on price, pharmacy contracts, manufacturing scale and national registration across mature UDCA formulations.
Asian suppliers expand the market through cost-competitive production, regional distribution and growing domestic hepatobiliary treatment demand.
Source: FDA ursodiol; AASLD.
August 2024: FDA approved LIVDELZI (seladelpar) for PBC in combination with UDCA in adults with inadequate response, or as monotherapy in patients unable to tolerate UDCA. The pivotal trial enrolled 193 patients.
June 2024: FDA approved IQIRVO (elafibranor) for PBC in combination with UDCA in adults with inadequate response, or as monotherapy when UDCA cannot be tolerated. The supporting trial enrolled 161 patients.
Current treatment cycle: The expansion of second-line PBC therapies is increasing emphasis on biochemical-response assessment while preserving UDCA as the first-line treatment backbone for most patients.
Source: FDA LIVDELZI; FDA IQIRVO; AASLD.
The global ursodeoxycholic acid drugs for hepatobiliary diseases market market is projected to grow from USD 1.50 billion in 2026 to USD 2.40 billion by 2034, at a 6.1% CAGR during 2026–2034. Growth is expected to be supported by long-duration PBC treatment, broader diagnosis, generic access and combination use in inadequate responders. The market will remain price-sensitive because the active ingredient is mature, but recurring therapy and geographic expansion provide a stable volume base.
| Forecast Variable | Current Evidence / Starting Point | Expected Effect Through 2034 |
|---|---|---|
| First-line standard | UDCA remains the mainstay of PBC treatment at 13–15 mg/kg/day. | Supports recurring chronic prescriptions. |
| Combination therapy | New FDA-approved PBC agents are used with UDCA in inadequate responders. | Preserves UDCA use while increasing treatment intensity. |
| Generic access | Multiple manufacturers compete across capsules and tablets. | Expands affordability and regional availability. |
| Gallstone niche | Actigall supports selected gallstone dissolution. | Provides a secondary application outside PBC. |
| Asia-Pacific growth | Regional manufacturing and specialist access continue to expand. | Supports higher prescription volumes in emerging hepatology markets. |
The study is structured to support strategy, market-entry assessment, portfolio planning, competitive benchmarking and commercial opportunity analysis across the global ursodeoxycholic acid drugs for hepatobiliary diseases market landscape.
24LifeScience develops ursodeoxycholic acid drugs for hepatobiliary diseases market market estimates using a combination of bottom-up and top-down assessment. Bottom-up work reviews relevant manufacturers, product portfolios, geographic presence, installation or utilization patterns, commercial channels and pricing structure. Top-down work evaluates the addressable testing or diagnostic environment, installed capacity, procedure or production demand, replacement and upgrade cycles, and regional access conditions.
Primary research is used to validate market structure, purchasing criteria, technology adoption, competitive positioning and operating constraints where available. Secondary research prioritizes regulators, government and public-health agencies, recognized standards, peer-reviewed or professional evidence, and company filings or official product communications. Clinical and regulatory evidence is checked against AASLD guidance and FDA labels and approval records. Second-line PBC products are treated as market influences rather than included in UDCA revenue, and exact segment shares are not introduced without defensible source support.
Forecasts incorporate the 2025 market base, 2026 estimated conditions, technology and regulatory developments, replacement or expansion demand, regional investment, pricing pressure, service requirements and competitive intensity. High-impact assumptions are cross-checked against authoritative evidence before publication.
The market was valued at USD 1.41 billion in 2025 and is estimated at USD 1.50 billion in 2026. It is projected to reach USD 2.40 billion by 2034 at a 6.1% CAGR during 2026–2034.
UDCA is used primarily for primary biliary cholangitis and also for selected gallstone dissolution and other hepatobiliary applications.
AASLD recommends oral UDCA at 13–15 mg/kg/day for PBC patients with abnormal liver tests.
Primary biliary cholangitis is the leading application because UDCA is the established first-line long-term therapy.
North America is the largest regional market, supported by strong diagnosis, specialist hepatology care and broad generic access.
Both drugs are approved for PBC in combination with UDCA in adults who have an inadequate response, so they add treatment options without broadly replacing UDCA.
Generic price competition, variable diagnosis rates and the availability of alternative or adjunctive hepatobiliary therapies can limit value growth.
The report profiles Dr. Falk Pharma, Daewoong, Teva, Viatris, Mitsubishi Tanabe, Lannett, Shanghai Pharmaceuticals, Grindeks and other UDCA manufacturers.
The standardized forecast period is 2026–2034, with 2025 as the base year and 2026 as the estimated year.
Display logos only where use is approved. A logo does not imply a public endorsement.
The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.
We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.
I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.
Their custom report on clinical trial trends was a helpful reference as we explored new indications.
As someone working on early product planning, I found their therapeutic-area briefs useful and easy to apply in our internal discussions.
We needed dependable data and a clearly presented market structure. The research gave us a practical starting point for our assessment.
Publish named testimonials only when the individual and organization have approved disclosure.
Review the report scope, forecast timeframe, methodology, and cited evidence before deciding whether the full study fits your requirement.
Coverage, segmentation, geography, and market boundaries are stated within the report.
Readers can review the published sources and evidence referenced in this market overview.
Base, estimated, and forecast years are shown to place the market outlook in context.
Each overview displays its report identifier and latest update date.
A structured view of market size, forecast outlook, segmentation, regional dynamics, competitive activity, and the research framework behind this study.
Review the market estimate, growth outlook, forecast direction, and key factors influencing future demand.
Understand the report’s defined segments, demand drivers, applications, end users, and market opportunities.
Assess regional performance, selected country context, and factors shaping adoption across major markets.
Explore company profiles, market positioning, and selected developments relevant to the market landscape.
Review key demand drivers, challenges, emerging opportunities, technology shifts, and factors influencing market direction.
Understand the report scope, market boundaries, research approach, and evidence referenced in the published market overview.